Европейски съюз -
български -
EMA (European Medicines Agency)
hemlibra
roche registration limited - emicizumab - Хемофилия А - Антихеморагични - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra могат да бъдат използвани във всички възрастови групи.
България -
български -
Изпълнителна агенция по лекарствата
octenisept 1 mg/ml + 20mg/ml cutaneous spray, solution
fgk representative service gmbh - 1 mg/ml + 20mg/ml cutaneous spray, solution
България -
български -
Изпълнителна агенция по лекарствата
ospen 400 000 iu/5 ml oral suspension
sandoz gmbh - Бензатин феноксиметилпенициллин - 400 000 iu/5 ml oral suspension
Европейски съюз -
български -
EMA (European Medicines Agency)
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - Аминокиселинен метаболизъм, вродени грешки - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.
